Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Non-Current Assets (2016 - 2025)

Cumberland Pharmaceuticals' Non-Current Assets history spans 16 years, with the latest figure at $39.8 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 1.62% year-over-year to $39.8 million; the TTM value through Dec 2025 reached $150.5 million, down 10.9%, while the annual FY2025 figure was $39.8 million, 1.62% up from the prior year.
  • Non-Current Assets for Q4 2025 was $39.8 million at Cumberland Pharmaceuticals, up from $36.0 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $51.4 million in Q1 2022 and bottomed at $36.0 million in Q3 2025.
  • The 5-year median for Non-Current Assets is $42.2 million (2021), against an average of $42.7 million.
  • The largest annual shift saw Non-Current Assets dropped 18.54% in 2021 before it increased 21.36% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $38.8 million in 2021, then rose by 21.36% to $47.1 million in 2022, then dropped by 2.28% to $46.0 million in 2023, then fell by 14.9% to $39.1 million in 2024, then increased by 1.62% to $39.8 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Non-Current Assets are $39.8 million (Q4 2025), $36.0 million (Q3 2025), and $36.7 million (Q2 2025).